Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.
暂无分享,去创建一个
Ying Zhou | Chenchen Zhu | Zhen Shen | Lili Qian | Juan Wang | Hanyuan Liu | Ying Wei | Xuefen Zhang | Weiguo Song | Da-Bao Wu
[1] Shona Morrison,et al. Outcomes of women diagnosed and treated for low‐risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC) , 2017, The Australian & New Zealand journal of obstetrics & gynaecology.
[2] J. Chen,et al. Bleeding from gestational trophoblastic neoplasia: embolotherapy efficacy and tumour response to chemotherapy. , 2017, Clinical radiology.
[3] Jun Zhao,et al. Fertility-sparing uterine lesion resection for young women with gestational trophoblastic neoplasias: single institution experience , 2017, Oncotarget.
[4] L. Havrilesky,et al. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? , 2015, Gynecologic oncology.
[5] R. Coleman,et al. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. , 2016, Gynecologic oncology.
[6] A. Gadducci,et al. Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. , 2016, Anticancer research.
[7] T. Lawrie,et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.
[8] P. Hanjani,et al. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial , 2016, International Journal of Gynecologic Cancer.
[9] R. Berkowitz,et al. Update on the diagnosis and management of gestational trophoblastic disease , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[10] R. Berkowitz,et al. Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. , 2015, Gynecologic oncology.
[11] A. Swerdlow,et al. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Seckl,et al. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom. , 2015, Gynecologic oncology.
[13] M. Hasanzadeh,et al. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia. , 2014, Journal of cancer research and therapeutics.
[14] R. Coleman,et al. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. , 2013, European journal of cancer.
[15] N. Sebire,et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] M. Gilani,et al. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. , 2013, Journal of cancer research and therapeutics.
[17] N. Sebire,et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 , 2012, British Journal of Cancer.
[18] A. Baptista,et al. Comparison of methotrexate, actinomycin D, and etoposide for treating low‐risk gestational trophoblastic neoplasia , 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[19] M. Thomas,et al. Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia. , 2012, The Journal of reproductive medicine.
[20] A. Rademaker,et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. , 2012, Gynecologic oncology.
[21] R. Berkowitz,et al. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. , 2012, The Journal of reproductive medicine.
[22] R. Berkowitz,et al. Current management of gestational trophoblastic neoplasia. , 2012, Hematology/oncology clinics of North America.
[23] H. Shojaei,et al. Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease , 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[24] Y. Xiang,et al. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] W. Kang,et al. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. , 2010, Gynecologic oncology.
[26] S. Wilailak,et al. Actinomycin D Versus Methotrexate-Folinic Acid as the Treatment of Stage I, Low-Risk Gestational Trophoblastic Neoplasia: A Randomized Controlled Trial , 2009, International Journal of Gynecologic Cancer.
[27] G. Chalouhi,et al. Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. , 2009, American journal of obstetrics and gynecology.
[28] Z. Sarraf,et al. Weekly intramuscular methotrexate in the treatment of low-risk gestational trophoblastic neoplasia , 2009, Archives of Gynecology and Obstetrics.
[29] D. Tiezzi,et al. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. , 2008, Gynecologic oncology.
[30] M. Burlea,et al. [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital]. , 2008, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.
[31] Yin Sun,et al. [Factors related to recurrence of choriocarcinoma and evaluation of treatment outcomes]. , 2006, Zhonghua fu chan ke za zhi.
[32] R. Coleman,et al. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects , 2003, British Journal of Cancer.
[33] FIGO staging for gestational trophoblastic neoplasia 2000 , 2002 .
[34] R. Klausner,et al. Perspective from the National Cancer Institute (NCI). , 1998, Breast disease.
[35] J. Weed,et al. The role of operation in the current therapy of gestational trophoblastic disease. , 1980, American journal of obstetrics and gynecology.